emedi-admin@emediwrite.com

Introduction Bringing your medications to market and establishing trust can be challenging processes. Healthcare professionals (HCPs) with substantial knowledge in particular therapeutic areas (TAs) of the pharmaceutical sector are known as key opinion leaders (KOLs) in the industry. Pharma companies need recommendations from professionals and word-of-mouth advertising. KOLs in the pharmaceutical industry are crucial in this situation. KOLs are primarily independent scientific and medical professionals who advise pharmaceutical firms on a variety of tasks, from pre-clinical and clinical stages of drug development research to clinical trials, regulatory approval, and product launch. KOL engagement helps pharmaceutical companies with new product development, data collection, strategy improvement, and creation of pertinent, reliable, and persuasive marketing messaging. KOLs in pharma: Benefits KOLs’ function in pharmaceutical market research Pharmaceutical companies look for KOLs with experience and expertise in their target therapeutic areas (TAs) to assist them with patient recruitment for clinical trials and data analysis. KOLs are crucial when it comes to spreading knowledge about new medications and treatments. In the medical community, they also give emerging treatments credence. A KOL can also instruct doctors on the physiological effects of a given medication and the types of patients who will benefit from it the most. Additionally, they can share information on treatment plans and describe their own firsthand knowledge of the therapies. Making a KOL engagement plan is therefore essential for brand acceptability in the pharmaceutical sector. The significance of KOL engagement KOL engagement, also known as KOL management, includes the full life cycle of selecting, evaluating, and working with the right KOLs in accordance with business objectives. It also includes planning research and marketing activities that involve them. KOL relationships should be based on trust and a shared desire for long-term cooperation. KOL engagement experiences an early rise, a plateau, and a gradual decline in involvement throughout the same lifecycle as the company’s products. Before recommending the best engagement strategy, pharma companies must ask pertinent questions to determine whether a particular KOL’s current work is in line with the company’s scientific and business goals. Choosing the best KOLs for your organization It is crucial to appropriately assess a KOL’s relative influence and TA proficiency. The following criteria can be used to assess a KOL’s strength based on their level of involvement, brand adoption, and influence behaviors: Learn how pharmaceutical companies utilized eMediWrite to partner with KOLs in their target TAs to create a panel of national experts across the country. Strong KOL management plans are essential for pharma companies in order to handle the shifting dynamics of KOLs in pharma.  An early KOL endorsement can generate a lot of attention in the industry and increase the efficacy of a breakthrough medication. But for pharmaceutical companies, finding, keeping, and managing KOLs has never been an easy task. Why and how eMediWrite can be useful Any KOL management procedure should be backed by thorough and reliable data sources. Additionally, the data is useless unless the right filters and analytics are applied to produce insightful results. As a result, businesses frequently turn to companies like eMediWrite. Global businesses can access full-service pharmaceutical market research services from eMediWrite in a variety of therapeutic areas. We combine local knowledge with deep insight from rigorously verified KOLs, including doctors, nurses, allied healthcare professionals, administrators, thought leaders, and payers. Contact us right away to learn more about how we can assist you.

From the examination of raw materials through the release of the finished packaged product, Quality Control Authorities like Central Drugs Standard Control Organisation in India established under the Drugs & Cosmetics Act, 1940. Central Drugs Standard Control Organisation (earlier known as Drugs Controller General of India) are essential to the pharmaceutical production process. They play a crucial role in assuring the efficacy and safety of products given to patients. The CDSCO headquarters conduct regulatory supervision over drug importation, approval of new pharmaceuticals and clinical trials, meetings of the Drugs Consultative Committee (DCC) and Drugs Technical Advisory Board (DTAB), and approval of some licences as the Central Licence Approving Authority. Laboratory Information Management Systems (LIMS), tailored to the needs of pharmaceutical manufacturing and quality assurance/quality control (QA/QC) laboratories, are proving to be a powerful force in enabling the industry to meet these challenges. Capable of integrating multiple functions and processes, these systems reduce reliance on off-line methods and manual transcription for managing, tracking and applying the large volume of data generated as part of manufacturing processes. As a result, laboratories can more easily identify cost reduction strategies, while meeting regulatory standards and ensuring the security of their data. Central Drugs Standard Control Organisation (QCA) provides one of the most crucial roles in pharmaceutical manufacture and supervision, according to the FDA. The quality control Authority and product testing are covered in great detail by the CGMP requirements. In order to manufacture pharmaceuticals products, the Central Drugs Standard Control Organisation is essential. The tests it does verify the quality of the products, and the reports it produces serve as the written proof. Tests conducted at different phases like Phase I, Phase II and Phase III of the production process create enormous volumes of data, which should show if quality has been maintained. Since any inaccuracies might lead to the production of goods that might be ineffective or endanger human safety, it is understandable that regulatory oversight of QC Authority data is rigorous. A company’s systems transparency may also be shown by such data.

The process of giving a pharmaceutical product a unique identity on the market is called pharmaceutical product positioning. It entails recognising the special qualities and advantages of your product and conveying them to the intended market in a way that sets it apart from rival goods. Your pharmaceutical firm can gain a competitive edge, boost sales, and develop brand loyalty by using effective product positioning. Consider the following SIX actions when positioning your pharmaceutical product: A thorough awareness of the target market and the competitive environment is necessary for effective pharmaceutical product positioning. Pharmaceutical firms can distinguish their goods and increase market potential by creating a clear and attractive positioning plan.

Knowledge marketing is a crucial method for influencing doctors’ prescription practises in the pharmaceutical business. Pharma marketers employ various knowledge marketing strategies and initiatives with the goal of influencing HCPs’ prescribing behaviour. These consist of: Pharmaceutical marketers typically don’t spend enough on patient education. However, HCPs increasingly favour pharmaceutical firms that place a greater emphasis on patient interaction and education. In various ways, patient education may be extremely influential in how doctors prescribe: By enhancing patient empowerment, lowering healthcare costs, and boosting adherence, patient education can significantly affect how doctors prescribe. Doctors may be more inclined to recommend medications and therapies that may effectively improve patient outcomes if patients are given educational information and tools.

Different types of video media are used in video marketing to advertise and market the goods and services offered by healthcare companies. An astounding 86% of healthcare companies use video marketing as a marketing strategy. Video has been shown to Although video marketing has been shown to be beneficial for all business kinds, it is especially well suited to the promotion of healthcare products since it can make complex information accessible to a large audience. Video production can be challenging; outsourcing it to a medical communications agency will simplify the process, allay any worries, and guarantee that your film is appealing, marketable, and matches your business’s goals.

The pharmaceutical sector is known for having a robust R&D and a sizable sales staff. However, over time, pharmaceutical businesses have encountered a number of difficulties, including high R&D costs, product patent expirations that coincide with price erosion, and the consolidation of pharmaceutical firms. Figure 1: The following illustrates a schematic view of the distinctions between the FMCG and pharmaceutical industries. There are stringent rules for the pharmaceutical industry. Because of this, the introduction of new products to the market moves slowly. Patent protection for pharmaceutical items is not very long. Contrary to FMCG products, pharmaceutical brands cannot be transferred after a patent expires. Brands of non-prescription pharmaceuticals, like Fast-Moving Consumer Goods (FMCG) items, can last for a very long time while those of prescription drugs only last for about ten years (Figure 1). Given modern science and technology, established trademarks become less significant when a new chemical is discovered that is more effective for a particular treatment. These “super brands” can endure the expiration of their patents and develop “a link with the consumer at a level exceeding basic functional performance.” On the other hand, FMCG businesses incorporate brand creation early in the process of developing a product. The distinction is that pharmaceutical businesses prioritise product development over brand building. The latter have not been as effective in harnessing brand power. Nevertheless, certain OTC medications have substantial advertising efforts in some markets, such as the United States. Because of this, branding in the pharmaceutical sector is ten years behind that of the FMCG sector. Advertising is a crucial component of brand growth, which takes time. In other markets, new threads within this paradigm, such as direct to consumer advertising (DTCA) have evolved . In a lot of nations, it is illegal to advertise prescription medications. The only two nations that permit DTCA for prescription pharmaceuticals when the consumer has little to no drug selection options are the United States and New Zealand. Additionally, advertisements that feature both the product and an associated indication are prohibited in Canada. Prescription medicine marketing initiatives are based on functional qualities of products, such as clinical and product-related features, in nations such as India where DTCA is not permitted. Promotion includes a variety of marketing initiatives that are primarily targeted at healthcare professionals, including personal sales, drug detailing, journal and software advertising, sponsorship of educational events, educational materials, promotional goods, public relations initiatives, and disease awareness campaigns (DACs). On the other hand, because OTC or non-prescription medications are available directly to consumers, there are no regulatory constraints on their use. Advertising of OTC goods to the general public is permitted. In many ways, OTC branding is similar to FMCG branding in that it aims to gain market share by achieving brand recognition, preference, and loyalty. Brands play a huge impact in OTC drug purchases since end users play a large role in this decision. Marketing strategies used in promotion include DTCA (including TV, radio, print commercials, etc.), details, sponsorship, events, direct mail, promotional items, public relations efforts, social media, and viral marketing. Promotion is aimed at both consumers/patients and healthcare professionals. The audience’s demands should be the first priority for OTC marketers because brand association and brand image are derived from consumer needs. There are three fundamental brand name strategies used by the FMCG industry. The terms “descriptive brand,” “new brand,” and “company brand” are used here. Pharmaceutical brand name tactics, on the other hand, use various emphasis points. These include the official name of the company (Novarapid-Novo Nordisk), the therapy (Procardia), the indication (Glucophage), the class (Mevacor/Zocor), the scientific name of the active ingredient (Indocin for Indomethacin), and a new brand name (Zantac, Prozac). Except for the well-known corporate and new brands, generic drugs can easily undermine a pharmaceutical brand’s positioning, image, or name recognition. Brand management must be careful since there are times when corporate and product brand names may be closely related and may have an impact on one another. For instance, Vioxx, a nonsteroidal anti-inflammatory medicine, was pulled from the market, which had a detrimental impact on the corporate brand of Merck.